News Sentiment

EW sentiment intelligence

Edwards Lifesciences Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 56 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 92.21 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-2.3% over one week, +8.3% over four weeks, trend active, and near fair-value range.

Latest direct headline Negative

Edwards Lifesciences pays $10M and creates antitrust compliance program under FTC judgment

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend active 8.3% over four weeks
Fair value 18.0% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 11
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Ad Hoc News 6
MT Newswires 5
Stock Titan 5
simplywall.st 5
MarketWatch 3
Investing.com Nigeria 3
Investing.com 3

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 17
Analyst action 6
Deals and strategy 4
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 56
Compliance Week Direct company coverage

Edwards Lifesciences pays $10M and creates antitrust compliance program under FTC judgment

Edwards Lifesciences Corp. will pay a $10 million penalty and establish an antitrust compliance program as part of a pending agreement with the U.S. Federal Trade Commission (FTC). This action stems from the company's failure to notify the FTC about its acquisition of JC Medical

Tone
Negative 29/100
Event
Deals and strategy
Published
16 Jul 2026 20:08
Source
Compliance Week
scanx.trade Direct company coverage

Edwards Lifesciences to announce Q2 results on July 23

Edwards Lifesciences will release its second-quarter operating results for 2026 after the market closes on July 23. The company will also host a conference call at 5:00 p.m. ET on the same day to discuss its financial performance. Investors can access the call via phone or webcas

Tone
Positive 70/100
Event
Earnings
Published
16 Jul 2026 12:35
Source
scanx.trade
Stock Titan Direct company coverage

Edwards Lifesciences Plans to Report June 30 Quarter Results July 23

Edwards Lifesciences (NYSE: EW) will announce its operating results for the quarter ended June 30, 2026, after the market closes on Thursday, July 23rd. The company will host a conference call on the same day at 5:00 p.m. ET to discuss these results. Interested parties can access

Tone
Neutral 50/100
Event
Earnings
Published
16 Jul 2026 11:04
Source
Stock Titan
MarketWatch Direct company coverage

Edwards Lifesciences Corp. stock underperforms Wednesday when compared to competitors

Edwards Lifesciences Corp. (EW) shares fell by 3.13% to $87.27 on Wednesday, marking its third consecutive day of losses. This underperformance occurred despite an overall favorable trading session where the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) both saw gai

Tone
Negative 29/100
Event
Market update
Published
15 Jul 2026 20:39
Source
MarketWatch
MarketWatch Direct company coverage

Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day

Edwards Lifesciences Corp. (EW) shares fell 1.85% to $90.09 on Tuesday, marking its second consecutive day of losses. Despite this decline, the stock still outperformed the broader market, as the S&P 500 Index rose 0.38% and the Dow Jones Industrial Average rose 0.02% in an other

Tone
Positive 64/100
Event
Market update
Published
14 Jul 2026 16:49
Source
MarketWatch
Moomoo Direct company coverage

Edwards Lifesciences, Genesis MedTech to Pay Combined $12M to Settle FTC Charges -- Update

Edwards Lifesciences and Genesis MedTech will pay a combined $12 million to settle Federal Trade Commission (FTC) charges related to their previous acquisition activities. The FTC alleged that Edwards Lifesciences acquired Genesis MedTech's heart valve business in 2022, which was

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 23:07
Source
Moomoo
Investing.com Nigeria Direct company coverage

Form 4 Edwards Lifesciences Corp For: 13 July By Investing.com

This article reports on a Form 4 filing for Edwards Lifesciences Corp (EW) on July 13. Form 4s indicate changes in ownership of company stock by insiders. The article provides the date of the filing but does not detail the specifics of the transactions.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:18
Source
Investing.com Nigeria
GuruFocus Direct company coverage

Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW)

Daniel Lippis, CVP, TAVR at Edwards Lifesciences Corp (EW), sold 619 shares of the company on July 10, 2026. This transaction leaves him with 40,033.9103 shares. The article also notes that Edwards Lifesciences Corp is currently trading at $91.7, which is fairly valued according

Tone
Negative 30/100
Event
Market update
Published
11 Jul 2026 00:46
Source
GuruFocus
Investing.com Nigeria Direct company coverage

Form 4 Edwards Lifesciences Corp For: 10 July By Investing.com

This article reports on a Form 4 filing for Edwards Lifesciences Corp for transactions made on July 10th. Form 4s disclose changes in beneficial ownership of securities by company insiders. The brief news item includes the company's stock symbol (EW) and its performance on the da

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:37
Source
Investing.com Nigeria
Investing.com Direct company coverage

Edwards Lifesciences CVP sells $56,762 in company stock

Daniel J. Lippis, CVP of TAVR at Edwards Lifesciences Corp (NASDAQ:EW), sold 619 shares of company stock for $56,762 after acquiring them through employee stock options. The transactions were conducted under a Rule 10b5-1 trading plan. Following the sale, Mr. Lippis retains over

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:37
Source
Investing.com
Stock Titan Direct company coverage

Edwards Lifesciences (EW) CFO receives stock, performance unit and option grants

The CFO of Edwards Lifesciences, Theodora Mistras, received new equity awards on July 9, 2026, as part of the company's Long-Term Stock Incentive Compensation Program. These awards include restricted stock units, performance-based restricted stock units, and employee stock option

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:11
Source
Stock Titan
Stock Titan Direct company coverage

Edwards Lifesciences (NYSE: EW) CVP exercises stock options and sells 619 shares

Daniel J. Lippis, CVP at Edwards Lifesciences, exercised stock options for 619 shares at $72.68 and immediately sold them at $91.70 per share on July 10, 2026. This transaction was pre-scheduled under a Rule 10b5-1 trading plan adopted in February 2026. Following these trades, Li

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:04
Source
Stock Titan
MarketWatch Direct company coverage

Edwards Lifesciences Corp. stock underperforms Thursday when compared to competitors

Edwards Lifesciences Corp. (EW) stock fell 2.47% on Thursday, closing at $91.33. This underperformance occurred despite a favorable trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both rising. This marks the third consecutive day of

Tone
Negative 36/100
Event
Market update
Published
09 Jul 2026 20:47
Source
MarketWatch
GuruFocus Direct company coverage

EW Maintained by Citigroup -- Price Target Raised to $110

Citigroup has maintained a "Buy" rating on Edwards Lifesciences (EW) and raised its price target from $101 to $110, indicating confidence in the company's growth opportunities. Despite this positive analyst outlook and a strong GF Score™ of 97/100, the stock is currently consider

Tone
Positive 71/100
Event
Analyst action
Published
08 Jul 2026 17:07
Source
GuruFocus
AD HOC NEWS Direct company coverage

Edwards Lifesciences focuses on heart valve growth as US cardiac demand stays solid

Edwards Lifesciences, a medical technology company, is prioritizing growth in heart valve therapies, especially TAVR, driven by solid demand in the US cardiac procedure market and an aging population. The company's strategy revolves around treating structural heart diseases with

Tone
Neutral 50/100
Event
Macro sensitivity
Published
08 Jul 2026 13:08
Source
AD HOC NEWS
Investing.com Nigeria Direct company coverage

Form 4 Edwards Lifesciences Corp For: 7 July By Investing.com

This article from Investing.com announces the filing of a Form 4 for Edwards Lifesciences Corp on July 7th. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they trade shares in their own company. This filin

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 00:02
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Edwards Lifesciences (EW) executive has shares withheld for tax on vesting

Edwards Lifesciences executive Daniel J. Lippis reported a routine disposition of 377 shares of common stock at $95.18 per share. This action was taken to cover tax obligations related to the vesting of equity awards, as per Rule 16b-3(e). After this tax-withholding event, Lippis

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 22:56
Source
Stock Titan